Bellecapital’s Bristol-Myers Squibb BMY Stock Holding History

Bellecapital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,152	Closed	-$587K	–	153
2019 Q4	$587K	Buy	9,152 +4,129	+82%	+$236K	0.3%	72
2019 Q3	$255K	Hold	5,023	–	–	0.15%	110
2019 Q2	$228K	Sell	5,023 -14,810	-75%	-$690K	0.14%	110
2019 Q1	$946K	Buy	19,833 +15,322	+340%	+$763K	0.6%	34
2018 Q4	$234K	Buy	+4,511	New	+$242K	0.17%	88

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bellecapital's BMY Position: Q1 2020 in Review

Bellecapital sold out of Bristol-Myers Squibb (BMY) in Q1 2020, closing a stake of 9,152 shares — an estimated $587K sold.

Bellecapital first reported a position in BMY in Q4 2018 and held it in 5 quarters. The position peaked at $946K in Q1 2019. 2,147 funds tracked by Wall St. Rank hold BMY as of Q1 2020.

Bellecapital reported no remaining Bristol-Myers Squibb position as of Q1 2020 after selling out during the quarter.
Bellecapital sold 9,152 Bristol-Myers Squibb shares in Q1 2020, an estimated $587K.
Bellecapital first reported a position in Bristol-Myers Squibb in Q4 2018 and held it in 5 quarters.
Bellecapital's Bristol-Myers Squibb position peaked at $946K in Q1 2019.
2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2020.

Based on Bellecapital's 13F filing for Q1 2020, filed 24 Apr 2020.